Newhouse M T, Corkery K J
Inhale Therapeutic Systems, San Carlos, CA 94070, USA.
Respir Care Clin N Am. 2001 Jun;7(2):261-75, vi. doi: 10.1016/s1078-5337(05)70033-2.
During the past 50 years, aerosol therapy with small molecules has become the mainstay for managing lung diseases such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. During the past decade, a new therapeutic paradigm has evolved-the delivery of macromolecules into the systemic circulation through the lung. Systemic pulmonary therapy with proteins and peptides resulted from major developments in dry powder drug formulations and aerosol delivery technology. These new technologies will enable the treatment of systemic disease, such as diabetes mellitus, noninvasively by means of the deep lung. Within a decade, it is likely that many medications will be administered in this way.
在过去50年里，小分子气雾剂疗法已成为治疗哮喘、慢性阻塞性肺疾病和囊性纤维化等肺部疾病的主要手段。在过去十年中，一种新的治疗模式逐渐形成——通过肺部将大分子输送到体循环。蛋白质和肽的全身肺部治疗源于干粉药物制剂和气溶胶递送技术的重大进展。这些新技术将使糖尿病等全身性疾病能够通过深肺进行无创治疗。在十年内，很可能会有许多药物以这种方式给药。
